Original Source(s)
Related Content
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
FDA approves serial liquid biopsy testing
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026
-
2 min
ECP 2026: Combined Approach Predicts Metastasis in Prostate Cancer
Integrating spatial transcriptomics and machine learning may predict lymph node metastasis in treatment-naive prostate cancer
September 17, 2026
-
3 min
